Safety of and serological response to a new canine distemper-parvovirus combination vaccine in domestic ferrets.

A novel CDV-CPV-2c bivalent vaccine appears safe and maintains protective CDV antibody titers in ferrets for at least two years.

Pet ferrets are commonly vaccinated against canine distemper virus (CDV) using multivalent canine vaccines, despite limited species-specific safety and efficacy data. This study evaluated a novel bivalent vaccine combining a live canine parvovirus type 2c (CPV-2c) strain and the live Onderstepoort CDV strain. In the CPV-2c safety arm, 16 ferrets received an overdose of the CPV-2c component; blood, feces, and tissue samples were analyzed for viral dissemination and shedding, and serum antibody titers were measured. All ferrets mounted a serological response to CPV-2c, but no evidence of viral dissemination or shedding was detected, supporting the safety of this vaccine strain in ferrets. For the CDV efficacy arm, five ferrets received two field-dose vaccinations; three of these received a booster at one year. CDV antibody titers remained above putative protective thresholds for the full two-year observation period, regardless of whether a booster was administered. The study acknowledges that the CDV serological findings are based on a small cohort, limiting the strength of conclusions. Overall, the CPV-2c component appears unlikely to disseminate or shed in ferrets following administration, and the combined CDV-CPV-2c vaccine appears capable of providing protective immunity against distemper for a minimum of two years. These findings provide initial evidence supporting the use of this bivalent vaccine as a species-appropriate option for ferret distemper prophylaxis.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.